NCT04478825TerminatedPhase 1
An Open Label, Proof of Mechanism Study to Explore the Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis
Bridge Biotherapeutics, Inc.1 site in 1 country2 target enrollmentStarted: June 1, 2021Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Sponsor
- Bridge Biotherapeutics, Inc.
- Enrollment
- 2
- Locations
- 1
- Primary Endpoint
- Endoscopic remission rate
Study Overview
Brief Summary
This is an open label, single-arm, proof of mechanism study to explore the efficacy and safety of rectally administered BBT-401-1S in subjects with ulcerative colitis.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 60 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female, of any race, ≥18 and ≤60 years of age on Day
- •Have been diagnosed with active distal UC for ≥3 months prior to Day 1, as determined by clinical and endoscopic evidence and documented in a histopathology evaluation.
- •Have UC that is restricted to between the descending colon and the rectum (ie, left sided distal colitis), with demarcation of the lesion confirmed by endoscopy.
- •Have a total Mayo score ≥6, an endoscopic subscore ≥2, rectal bleeding subscore ≥1, and a stool frequency subscore ≥1.
Exclusion Criteria
- •Have used any biologics or Janus kinase (JAK) inhibitors including, but not limited to, anti TNF α biologics or tofacitinib for the treatment of UC.
- •Have used any purine analogues (azathioprine, mercaptopurine, or thiopurines) or immunosuppressants (methotrexate or cyclosporine) for the treatment of UC within 12 weeks or have any history of nonresponse to these medications.
- •Have used any rectal therapy for the treatment of UC with exception of rectal suppository of 5-aminosalicylic acid, or any intravenous corticosteroids within 2 weeks prior to Day
- •Have received oral and/or rectal suppository 5-aminosalicylic acid, oral sulphasalazine, or low-dose oral corticosteroids that have been stable for <4 weeks. Doses of the drugs must remain stable until the last dose of study drug.
- •Have received any other concomitant medications for UC that have been stable (ie, have not started dosing with a new drug or had a change to their dosing regimen) for <7 days or 5 half lives, whichever is longer, prior to Day
- •Have Crohn's disease, indeterminate colitis, ischaemic colitis, fulminant colitis, toxic megacolon, chronic pancolitis, or symptomatic intestinal stenosis.
- •Have a history of extensive colonic resection (subtotal or total colectomy) or are anticipated to require surgical intervention for UC.
- •Have an ileostomy or colostomy.
- •Have evidence of treatment for Clostridium difficile infection or other pathogenic bowel infection within 60 days or for another intestinal pathogen within 30 days prior to Day 1.
Arms & Interventions
BBT-401-1S
Experimental
BBT-401-1S, rectal administration
Intervention: BBT-401-1S (Drug)
Outcomes
Primary Outcomes
Endoscopic remission rate
Time Frame: Day 57
measured by a Mayo endoscopic subscore of 0 or 1
Secondary Outcomes
- Endoscopic response rate(Day 57)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
A Clinical Study to Assess the Safety and Effectiveness of Test Product in Healthy Adult Human Subjects Having Symptoms of Gut Dysbiosis (Heart Burn, Bloating, Constipation and Gut Immunity).Gut DysbiosisNCT06572358NovoBliss Research Pvt Ltd14
Unknown
Phase 3
Philippine Trial to Determine Efficacy and Safety of Favipiravir for COVID-19Covid19NCT05014373University of the Philippines144
Terminated
Phase 2
MMV390048 POC in Patients With P. Vivax and P. Falciparum MalariaMalariaNCT02880241Medicines for Malaria Venture8
Completed
Phase 2
Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD SubjectsNon-alcoholic Fatty Liver DiseaseHypercholesterolemiaNon-alcoholic SteatohepatitisHypertriglyceridemiaNCT02681055MediciNova19
Recruiting
Early Phase 1
CS-206 in Patients With Sickle Cell DiseaseSickle Cell DiseaseNCT06565026CorrectSequence Therapeutics Co., Ltd5